Cancer Genetics: Oncogenes, Tumor Suppressors, and Mutations | MIT 7.013

Added:

The Tissue Organization Field Theory (TOFT)

While the Somatic Mutation Theory (SMT) posits that cancer is a cell-based genetic disease driven by mutations in oncogenes and tumor suppressors, the Tissue Organization Field Theory (TOFT) offers an alternative paradigm. TOFT argues that cancer is a tissue-level disease rather than a cellular one. According to this perspective, carcinogenesis is not initiated by intracellular genetic mutations, but rather by the disruption of chemical and physical interactions between cells and their surrounding extracellular microenvironment (the tissue field). TOFT views proliferation as the default state of all cells, suggesting that cancer arises when tissue organization fails to restrain this default state, rather than being 'driven' by newly acquired genetic mutations. This shift in focus from the genome to tissue ecology challenges the reductionist genetic paradigm and suggests novel therapeutic approaches targeting the tissue microenvironment rather than specific genetic mutations.

The Central Dogma of Molecular Biology: Understanding how DNA is transcribed into RNA and translated into functional proteins.
The Eukaryotic Cell Cycle: Familiarity with the phases of cell division (G1, S, G2, M) and the general concept of cell cycle checkpoints.
Basic Genetics and Types of Mutations: Knowledge of how DNA mutations (e.g., point mutations, deletions, duplications) alter genetic code and protein expression.
Normal Cellular Signaling Pathways: Understanding how external signals (like growth factors) trigger intracellular cascades to promote cell growth or survival.
The Hallmarks of Cancer: Exploring the comprehensive framework of biological capabilities acquired by cells during the multistep development of human tumors.
Targeted Cancer Therapies: Studying how molecularly targeted drugs (such as tyrosine kinase inhibitors) specifically inhibit the proteins encoded by oncogenes.
Cancer Immunotherapy: Learning how the immune system interacts with cancer cells and how therapies like checkpoint inhibitors unleash the immune response against tumors.
Precision Medicine and Tumor Profiling: Investigating how DNA sequencing technologies identify patient-specific mutations to guide personalized cancer treatment strategies.
41.8K views598likes50:24@mitocwOriginal Release: 2014-01-15

Cancer develops through the accumulation of mutations in two classes of genes: oncogenes (which promote cell proliferation when mutated) and tumor suppressor genes (which normally inhibit proliferation and require two hits to be inactivated). Oncogenes are typically activated by gain-of-function mutations (like the RAS mutation causing constitutive signaling), while tumor suppressors like RB are inactivated by loss-of-function mutations. This understanding enables molecular diagnostics and targeted therapies for personalized cancer treatment.